EXPERTISE PARTNER
Answer ALS
Answer ALS is the single largest & most comprehensive ALS research project in history, producing more ALS data than has ever been amassed, while openly sharing with the global research community. The program coordinates with over 20 institutions, establishing a critical foundation for new clinical trials and developing new ways to categorize ALS patients to identify specific druggable pathways in an effort to make ALS a treatable disease. Since opening the Answer ALS data repository, Neuromine, in 2021, over 300 independent ALS research projects have begun worldwide from free access to the rich data and available samples.
Alamar Biosciences
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels in liquid biopsy samples. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method reducing background signal and increasing sensitivity and dynamic range compared with standard approaches. The NULISA Platform allows for a fully automated workflow with the ARGO™ System enabling less than 30 minutes hands-on time from sample to data.
www.alamarbio.com
Neurizon Therapeutics
Neurizon Therapeutics Limited, formerly known as PharmAust, is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon strategy is to accelerate access to effective ALS treatments for patients, while exploring NUZ-001’s potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.
EXCLUSIVE LEAD PARTNERS
Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through the Company’s unparalleled sensitivity and flexibility. Its industry-leading Simoa® precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding, management and patient care in neurology, oncology, immunology, cardiology and infectious disease for nearly two decades.
PROGRAM PARTNERS
Unlearn Ai
Unlearn is a San Francisco-based technology company pioneering generative machine learning methods to eliminate trial and error in medicine. Unlearn’s technology using patient digital twins is regulatory-qualified and used by leading global pharmaceutical companies to run AI-powered clinical trials that reach full enrollment faster and bring new treatments to patients sooner.
EXHIBITION PARTNERS
BrainXell
BrainXell provides high-purity, iPSC-derived human neurons and glia for research and development with a focus on drug discovery. Utilizing proprietary technology, we generate high-purity, subtype-specific neurons that mature rapidly and are quickly and easily ready for a variety of assays. Multiple neuron subtypes relevant to a range of disorders are available. Additionally, each neuron subtype can be made in custom batches from 50 million to 10 billion neurons from unique iPSC lines. We are dedicated to delivering the highest quality products for off-the-shelf neurons and custom service projects.
Transpharmation
Transpharmation is an accredited preclinical contract research organization specializing in translational pharmacology across various therapeutic areas. We offer neuroscience expertise, utilizing behavioral and molecular assays to help clients benchmark compounds. With extensive experience in antibiotic treatments and diet manipulations, we study their effects on the microbiome. Committed to on-time data delivery and providing flexible, customized solutions, we support clients in optimizing preclinical assets for the development of life-changing medicines
www.transpharmation.com
Axol Biosciences
Axol Bioscience is the leading manufacturer of functional iPSC-derived cells and provider of outsourced services to support ALS drug discovery programs. We manufacturer functional iPSC-derived motor neurons, microglia and astrocytes, building co-culture model systems with relevant endpoints. iPSCs? What can we do to help.
https://axolbio.com/
Anatomic Inc.
Anatomic Incorporated is the global leader in scalable production of high-purity motor neurons in just 7 days and Schwann cell precursors in 9 days from pluripotent stem cells, using only small molecules and growth factors. All cells are validated for purity and function, with plug-and-play protocols designed for screening and disease modeling. Custom differentiations from patient-derived lines—including ALS, CMT, and other neurological disorders—can be completed within 1–2 months and co-cultured for advanced model systems.
https://www.anatomic.com/
EVENT PARTNERS
Atlantic Research Group
ARG is a contract research organization focused on oncology, immunology, and neurology, providing comprehensive clinical program development services ranging from planning to commercialization, achieving over 50 market authorizations to date. Founded in 2004 with the vision that every project should be highly individualized, ARG has experienced consistent growth across the globe, expanding our range to include drug and device strategic consulting, clinical trial management services, as well as clinical data and analytic solutions. ARG uses first-in-class technology platforms along with relationship-driven flexibility to optimize clinical studies because we believe everyone deserves to be well.
Catalent
Zydis® orally disintegrating tablet (ODT) technology creates a unique, freeze-dried oral solid dosage form that disperses almost instantly in the mouth, without water. With more than 35 products launched in 60+ countries, Zydis is the world’s fastest and best-in-class ODT. Zydis has advantages over conventional oral dosage forms, including improved patient compliance, adherence and convenience, particularly within certain patient populations such as geriatrics, pediatrics and patients suffering from dysphagia. Catalent’s 250,000-square-foot site in Swindon, U.K., houses the Zydis development and manufacturing operation, which produces over 1.2 tablets annually.
https://www.catalent.com
NeuroSpector
Neurospector aims to improve drug development for neurological and psychiatric disorders by advanced testing of compounds on human neurons. Combining 20 years of experience in neuronal functioning enables us to study disease-relevant mechanisms in neurons. We are based in Amsterdam, where fundamental and clinical neuroscience research comes together in an interdisciplinary setting of academic medical centers and top universities.